Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
复制标题
DOI：
10.1038/s41591-023-02526-x
复制
发表时间：
2023-09
期刊：
影响因子：
82.9
通讯作者：
Kosiborod, Mikhail N.
中科院分区：
文献类型：
--
作者：
Borlaug, Barry A.;Kitzman, Dalane W.;Davies, Melanie J.;Rasmussen, Soren;Barros, Eric;Butler, Javed;Einfeldt, Mette Nygaard;Hovingh, G. Kees;Moller, Daniel Vega;Petrie, Mark C.;Shah, Sanjiv J.;Verma, Subodh;Abhayaratna, Walter;Ahmed, Fozia Z.;Chopra, Vijay;Ezekowitz, Justin;Fu, Michael;Ito, Hiroshi;Lelonek, Malgorzata;Melenovsky, Vojtech;Nunez, Julio;Perna, Eduardo;Schou, Morten;Senni, Michele;van der Meer, Peter;Von Lewinski, Dirk;Wolf, Dennis;Kosiborod, Mikhail N.
在STEP-HFpEF试验中，Semagluide改善了心力衰竭和射血分数(HFpEF)保留的肥胖表型患者的症状、身体限制和运动功能，并减轻了体重。这项预先指定的分析研究了赛马路德对I-III级肥胖(体重指数30.0-34.9 kg m−2)的双重主要终点(堪萨斯城心肌病问卷-临床总结评分和体重的变化)和确证次级终点(6分钟步行距离(6MWD)的变化，分级合成(死亡、心力衰竭事件，KCCQ-CS和6MWD的变化)以及C反应蛋白(C-反应蛋白)的影响。35.0~39.9 kg m−2和≥40 kg m−2)，并在52 周后按体重减轻。赛马路德一致地改善了肥胖类别的所有结果(治疗效果的P值 × 体重指数交互作用 = 对所有人都不显著)。在接受赛格路德治疗的患者中，体重下降越大，KCCQ-CS、6MWD和CRP的改善越明显(例如，体重每下降10%，KCCQ-CS和6MWD的改善分别为6.4分(95%可信区间：4.1、8.8)和14.4分(95%可信区间：5.5、23.3))。在HFpEF肥胖表型的参与者中，Semagluide改善了症状、身体限制和运动功能，并在肥胖类别中减少了炎症和体重。在接受赛格路德治疗的患者中，受益的程度与体重减轻的程度直接相关。总而言之，这些数据支持赛马路德介导的减肥作为HFpEF肥胖症表型患者的关键治疗策略。ClinicalTrials.gov标识符：NCT04788511。在对STEP-HFpEF试验进行的预先指定的二次分析中，赛格列德治疗与不同肥胖类别的KCCQ-CS和体重以及试验次级终点的改善有关，其益处的大小与体重减轻的程度成正比。
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m−2, 35.0–39.9 kg m−2 and ≥40 kg m−2) and according to body weight reduction with semaglutide after 52 weeks. Semaglutide consistently improved all outcomes across obesity categories (P value for treatment effects × BMI interactions = not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence interval (CI): 4.1, 8.8) and 14.4-m (95% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511. In a prespecified secondary analysis of the STEP-HFpEF trial, semagludtide treatment was associated with improvements in KCCQ-CSS and body weight, as well as trial secondary endpoints, across the spectrum of obesity classes, with the magnitude of beneficial effects being proportional to the extent of weight loss.
登录
查看更多内容
影响因子：
39.3
作者：
Adamson, Carly;Kondo, Toru;Jhund, Pardeep;de Boer, Rudolf A.;Honorio, Jose Walter Cabrera;Claggett, Brian;Desai, Akshay S.;Gamba, Marco Antonio Alcocer;Al Habeeb, Waleed;Hernandez, Adrian F.;Inzucchi, Silvio E.;Kosiborod, Mikhail N.;Lam, Carolyn S. P.;Langkilde, Anna Maria;Lindholm, Daniel;Bachus, Erasmus;Litwin, Sheldon E.;Martinez, Felipe;Petersson, Magnus;Shah, Sanjiv J.;Vaduganathan, Muthiah;Vinh, Pham Nguyen;Wilderang, Ulrica;Solomon, Scott D.;McMurray, John Jv
通讯作者：
McMurray, John Jv
影响因子：
24
作者：
Sorimachi, Hidemi;Obokata, Masaru;Omote, Kazunori;Reddy, Yogesh N., V;Takahashi, Naoki;Koepp, Katlyn E.;Ng, Arnold C. T.;Rider, Oliver J.;Borlaug, Barry A.
通讯作者：
Borlaug, Barry A.
DOI：
10.1001/jama.2015.17346
发表时间：
2016-01-05
期刊：
JAMA
影响因子：
--
作者：
Kitzman DW;Brubaker P;Morgan T;Haykowsky M;Hundley G;Kraus WE;Eggebeen J;Nicklas BJ
通讯作者：
Nicklas BJ
影响因子：
39.3
作者：
Sorimachi, Hidemi;Obokata, Masaru;Borlaug, Barry A.
通讯作者：
Borlaug, Barry A.
影响因子：
24
作者：
Dalos, Daniel;Mascherbauer, Julia;Bonderman, Diana
通讯作者：
Bonderman, Diana